ASX Health Stocks: Inoviq gets Brazilian patent for the use of BARD1 on lung and colorectal cancer
Health & Biotech
Health & Biotech
Link copied to
Inoviq (ASX:IIQ) has been granted a Brazilian patent covering the use of BARD1 isoforms in lung and colorectal cancer.
Specifically, the patent covers a method for detecting the presence of the specific BARD1 isoforms, and a method for discriminating lung cancer and colorectal cancer in body fluids.
“There is an important unmet medical need for non-invasive, accurate and reliable tests for earlier detection of lung cancer to improve health outcomes,” said CEO Dr Leearne Hinch.
“This patent provides IP protection for a potential BARD1 autoantibody test for lung cancer in Brazil,” she said.
This BARD1 patent family now has 13 granted patents enforcing protection in Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Singapore and the USA.
Meanwhile, researchers from the MD Anderson Cancer Center in Texas have identified additional Zantrene drug combinations with superior efficacy in AML cells.
This study, sponsored by Race Oncology (ASX:RAC), has been published in the Journal Leukemia & Lymphoma.
The MD Anderson team identified synergism of Zantrene, which is Race’s lead drug, and venetoclax in combination with panobinostat, decitabine, or olaparib (all known inhibitors of BCL2), histone deacetylase, DNA methyltransferase, and poly (ADP-ribose) polymerase, respectively, in AML cells.
Dr Daniel Tillett, Race CEO said: “This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML trial in Australian and Europe, where patients will be treated with Zantrene in combination with decitabine or cytarabine.”
“We are extremely excited about being able to quickly translate this work from the lab into the clinic, where it has the potential to help AML patients in need.”
Revenue of $1.33b vs $1,338bn on pcp
NPAT of $245.6m vs $223.2m on pcp
Healius played a pivotal role in Australia’s public health response to the Delta and Omicron outbreaks and PCR testing was the main driver of growth.
During the half, Healius also finalised the acquisition of Axis Radiology and announced the acquisition of Agilex Biolabs and the development of Murdoch Day Hospital.
Revenue of $364.2 million, up 3% on pcp.
Statutory net loss after tax of $3.7 million.
The aged company says it anticipates ongoing additional costs in both outbreak and non-outbreak homes during the second half of the financial year.
These added costs will come in the form of staff expenses and infection prevention and control including the use of personal protective equipment (PPE) and rapid antigen test kits.